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Abstract
Background Few studies have reported changes of bone
mineral density (BMD) after parathyroidectomy in patients
with persistent hyperparathyroidism after renal transplan-
tation (3 HPT).
Patients and Methods We retrospectively analyzed 14
patients who underwent successful parathyroidectomy for 3
HPT and who had available BMD data before and after
parathyroidectomy.
Results Median follow-up time was 26 months (IQR:
16.8–40.2). Serum calcium levels decreased significantly
after parathyroidectomy (2.32 ± 0.09 versus
2.66 ± 0.16 mmol/l; p \ 0.01), as did PTH levels
(5.1 ± 3.0 versus 27.8 ± 23.7 pmol/l; p \ 0.01). Nine
patients (64%) had a steroid-free immunosuppression at
follow-up. Mean increase in BMD was 9.5 ± 8.0% for the
spine and 9.5 ± 7.9% for the hip (p \ 0.01 for both sites).
Patients with osteoporosis (T-score B 2.5) or osteopenia
(T-score B 1) before parathyroidectomy had the biggest
increase in BMD (10.7 ± 7.7% in hip BMD and of
12.3 ± 8.1% in spine BMD).
Conclusions Parathyroidectomy is an efficient treatment
of osteoporosis and osteopenia in patients with 3 HPT.
Introduction
Chronic renal failure (CRF) is associated with a cascade of
events affecting mineral metabolism and leading to renal
osteodystrophy. In CRF, the deficient production of calci-
triol by the kidney and the bone resistance to PTH action
lead to hypocalcemia. Phosphorus retention due to the
decreased filtration rate and hypocalcemia are both a strong
stimulus to the parathyroid glands, leading to an increased
proliferation of parathyroid cells and an increased PTH
secretion called ‘‘secondary hyperparathyroidism.’’ Sec-
ondary hyperparathyroidism in CRF leads to osteitis fibrosa
cystica and osteopenia [1–3].
Tertiary hyperparathyroidism after renal transplantation
(3 HPT) is defined as persistent hypercalcemia after suc-
cessful renal transplantation and can be observed with an
incidence of 30 to 50 percent [4, 5]. However, in most
patients, the hypercalcemia resolves in a few months, and
only a few percent of patients will need parathyroidectomy
[5, 6]. The mechanism of refractory PTH hypersecretion
after renal transplantation is due in part to a too high
parathyroid cell mass, leading to an inappropriately high
basal PTH secretion (diffuse parathyroid hyperplasia); it
may also result from parathyroid adenomas that have
developed during the course of secondary HPT (nodular
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hyperplasia), with parathyroid cells having an abnormal
PTH secretion curve in response to calcium [7]. The high
PTH levels lead to increased renal tubular reabsorption of
calcium and to increased bone resorption, both mechanisms
causing hypercalcemia.
In the course of renal failure, the bone becomes resistant
to the action of PTH, one of the leading causes of hypo-
calcemia in secondary HPT. After renal transplantation, the
bone recovers its sensitivity to PTH, and the high PTH
levels found in 3 HPT after renal transplantation lead to an
accelerated bone turnover and then to a rapid loss of bone
mass [8]. Immunosuppressive therapy also leads to bone
loss; corticosteroids reduce bone formation and increase
bone resorption [9, 10], and calcineurin inhibitors (cyclo-
sporine and tacrolimus) induce osteopenia [8]. The fall in
bone mass density (BMD) is more consistent during the
first post-transplant months, with a rate of bone loss of
1.6% per month during the first 5 months, and it usually
continues after that period but at a slower rate [8, 11].
In case of persisting 3 HPT after renal transplantation,
the only effective treatment is parathyroidectomy, which
corrects the calcium levels in more than 80% of the
patients in the long term in experienced centers [12–15].
However, the long-term effect on bone mass has rarely
been reported. Therefore, the aim of this retrospective
study was to evaluate the effect of parathyroidectomy on
BMD in patients with 3 HPT after renal transplantation.
Patients and method
From October 1992 to October 2005, 19 patients under-
went parathyroidectomy at the University Hospital of
Geneva (15 patients) and at Sankt-Gallen KantonsSpital,
Sankt-Gallen, Switzerland (4 patients) for 3 HPT, defined
as 2 HPT that did not regress after successful renal trans-
plantation. Among these 19 patients, 5 were excluded from
our study; 2 because of persistent 3 HPT after surgery (one
had a missed fourth gland and was successfully reoperated
after the end of this study and the other had a subtotal
parathyroidectomy and is currently under medical treat-
ment), 2 died prematurely of a nonsurgical etiology without
enough follow-up, and 1 was lost to follow-up. Patients
were transplanted between 1986 and 2004. The immuno-
suppression regimen varied among the different timing of
transplantation, but most of the patients were on a cyclo-
sporin, mycophenolate mofetil, and steroid regimen begun
immediately after transplantation. Induction with IL2-R
(Basiliximab) was used beginning in 2000. Steroids were
withdrawn when possible. All patients were followed from
the initiation of dialysis by a team of nephrologists,
transplant surgeons, and bone specialists. All patients
received appropriate calcium and vitamin D
supplementation before parathyroidectomy (according to
the serum and urinary calcium levels) and after parathy-
roidectomy. All patients with osteoporosis received
bisphosphonates during the first year after transplantation.
The criteria for surgery were persistent hypercalcemia
(calcium level greater than 2.6 mmol/l) with a raised PTH
concentration (PTH level greater than 6.8 pmol/l) usually
longer than 1 year after kidney transplantation. The pro-
cedure was an intended subtotal parathyroidectomy, which
is defined as bilateral neck parathyroid exploration, leaving
a remnant the size of two normal parathyroid glands.
Outcomes were based on review of the surgery,
nephrology, and bone disease specialist case records,
including demographic data, history of end-stage renal dis-
ease, cumulative dose of corticoid, and pre- and
postoperative values of patients’ weight, serum creatinine,
calcium, and PTH. The two biological markers used in
Geneva only to evaluate bone turnover were serum osteo-
calcin and the ratio of urinary D-pyridinolin/creatinin for
formation and resorption, respectively. Bone mineral density
values at the lumbar spine (L1–L4) and proximal femur were
measured with dual energy x-ray absorptiometry the year
before parathyroidectomy and regularly thereafter to assess
the effects of medical and surgical treatments. Different
measurements in each patient were performed with the same
machine. At both sites, BMD is expressed in T-scores, which
is the number of standard deviation (SD) between the mea-
sured values and the mean BMD for a control group
composed of patient with same gender, aged from 25 to 35.
Therefore definitions of normal, osteopenic, and osteopo-
rotic patients are, respectively, C -1 SD, -1 to -2.5 SD,
and \ -2.5 SD. Glomerular filtration rate (GFR) was cal-
culated using the Cockroft and Gault formula [16]. The
cumulated dose of corticoid is in prednisone equivalent. It is
calculated from the first renal graft and included the loading
dose, the graft rejection dose, and the everyday dose.
Statistical analysis
Parameters with normal distribution are expressed as
mean ± SD. Parameters with skewed distribution are
expressed as median and interquartile range (IQR). Sta-
tistical analysis was performed with SPSS software (SPSS,
Chicago, IL). Comparisons between preoperative and
postoperative values of BMD, T-score, serum calcium,
serum PTH, serum osteocalcin, urinary D-pyridinolin/
creatinin, and GFR were made with a paired t-test. A value
of p \ 0.05 was considered statistically significant.
Results
Fourteen patients (7 males, 7 females) underwent successful
parathyroidectomy for 3 HPT after renal transplantation.
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Age at parathyroidectomy was 50.0 ± 10.1 years. Delay
from first dialysis to renal transplantation was 27 months
(IQR: 6.0–68.2). Two patients experienced failure of a first
kidney graft and underwent, respectively, two and three renal
transplantations before parathyroidectomy. Delay from last
transplantation to parathyroidectomy was 19 months (IQR:
9.8–55.2). Cumulated prednisone dose at parathyroidectomy
was 7.2g (IQR: 4.3–22.9). Twelve patients had subtotal
parathyroidectomy, one patient had total parathyroidectomy
with autotransplantation, and one patient needed three
operations to have PTH in the normal range: he first under-
went an intended total parathyroidectomy at another medical
center for 2 HPT while on dialysis. He was referred to our
center after recurrence of 2 HPT, and he underwent a
selective right inferior parathyroidectomy, according to the
concordant results of preoperative sestamibi scan and
ultrasound. After kidney transplantation, he presented per-
sistent/recurrent HPT and underwent a selective left inferior
parathyroidectomy, at which a 270 mg hyperplastic para-
thyroid gland was removed. There were no perioperative
deaths in our series. One patient has persistent hypopara-
thyroidism and is receiving calcium and vitamin D
substitution. Laryngoscopy was not routinely performed, but
no patient had postoperative dysphonia. Preoperative and
follow-up characteristics of the patients are summarized in
Table 1.
Follow-up time was 26 months (IQR: 16.8–40.2) after
parathyroidectomy. No patient was hypercalcemic at fol-
low-up, and all patients had PTH in the recommended
target range according to renal function [1]. Nine patients
(64%) had a steroid-free immunosuppression regimen, two
patients had 2.5 mg of prednisone, one patient 5 mg and
two patients 7.5 mg at follow-up. One patient had only
measurement of preoperative spine BMD; all others had
pre- and postoperative hip and spine BMD measurements.
Patients had two to five BMD measurements during follow-
up according to length of follow-up.
All patients increased their hip BMD, except one who
decreased it by 2% and who had the highest preoperative
BMD (Fig. 1). Similarly, all patients increased their
spine BMD except one, who decreased it by 5% (Fig. 2)
Mean increase in BMD was 9.5 ± 8.0% for the spine
and 9.5 ± 7.9% for the hip, corresponding to a mean
yearly increase of 3.8 ± 3.3% for the spine and
4.3 ± 4.8% for the hip. Patients with significant bone
loss preoperatively (osteoporosis or osteopenia, T-score
B 1) had an increase of 10.7 ± 7.7% in hip BMD and of
12.3 ± 8.1% in spine BMD. Before parathyroidectomy,
2 patients were osteoporotic at the spine and 3 at the
hip, and six were osteopenic at the spine and 8 at the
hip. At follow-up, no patient was osteoporotic, either at
the spine or at the hip, and three were osteopenic at the
spine and 7 at the hip. All sites combined, 5 patients
changed from osteoporosis to osteopenia and 8 from
osteopenia to normal BMD. Patients with more BMD
loss (worse T-score) had the biggest increase in BMD
(Fig. 3). The increase in BMD was higher in patients
without steroids at follow-up; however, the difference
was not significant, possibly because of the small sample
size (10.1 ± 8.9% versus 8.5 ± 6.8% for the spine and
10.2 ± 4.9% versus 8.2 ± 11.9% for the hip). Similarily,
a decrease in serum osteocalcin and urinary D-pyridin-
olin/creatinin ratio suggested a decrease in bone
turnover. However, these changes were statistically not
significant.
Discussion
The aim of this retrospective study of patients with 3 HPT
after renal transplantation was to investigate the effect of
parathyroidectomy on BMD. We found that parathyroid-
ectomy significantly increased postoperative BMD in 25 of
27 sites studied in 14 patients.
Table 1 Preoperative and follow-up characteristics of patients undergoing parathyroidectomy for 3HPT after renal transplantation
Characteristics Preoperative Follow-up p Values
Serum calcium level (mmol/l) (ref 2.2–2.52) 2.66 ± 0.16 2.32 ± 0.09 \0.001
Serum PTH level (pmol/l) (ref 1.1 - 6.8) 27.8 ± 23.7 5.1 ± 3.0 0.004
GFR ( ml/min) 67.6 ± 23.5 59.2 ± 28.0 0.094
Serum osteocalcin (g/l) (N = 7) 31.5 ± 18.9 23.1 ± 18.2 0.59
Urinary D-pyridinolin/creatinin (nmol/mmol) (N = 7) 12.4 ± 3.9 9.1 ± 2.8 0.234
BMD at spine (g/cm2) 0.977 ± 0.176 1.061 ± 0.146 \0.001
BMD at proximal femur (g/cm2) 0.748 ± 0.124 0.825 ± 0.125 0.002
T-score at spine (SD) -1.0 ± 1.4 -0.3 ± 1.1
T-score at proximal femur (SD) -1.8 ± 0.8 -1.1 ± 0.8
GFR glomerular filtration rate; BMD bone mass density; ref reference range
Results are mean ± SD
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Among 19 patients who underwent surgery for 3 HPT
after renal transplantation in both centers, one patient was
lost to follow-up and 2 were excluded because of persis-
tent/recurrent HPT. Therefore, parathyroidectomy was
effective in normalizing calcium and PTH levels in 16 of
18 patients (89%), similar to the long-term cure rate of
70%–100% reported in other series, the difference in cure
rate being mainly due to the different criteria used [12–15,
17–19].
Very few studies on parathyroidectomy for tertiary
hyperparathyroidism after renal transplantation have
reported the long-term effect on bone mass, although some
have reported the change in total alkaline phosphatase. In
the study by Seehofer et al., the results are given for sec-
ondary and tertiary patients together [20]. Sitges-Serra and
Caralps-Riera reported a decrease from 186 ± 153 IU/l to
77 ± 33 IU/l [21], and Nichol et al. reported a decrease
from 195.9 U/l to 94.7 U/l [13].
One study, by Abdelhadi and Nordenstrom, on bone
recovery after parathyroidectomy in patients with primary
and renal hyperparathyroidism (patients on dialysis and
patients after renal transplantation) reported an ‘‘only
marginal increase’’ in BMD after parathyroidectomy in
patients with 3 HPT [22]. Data taken from the graph show
that total body, lumbar spine, and femoral neck BMD
increased by about 2.1 ± 1.1%, 4.4 ± 2.1%, and 2.2 ±
3.3% (mean ± sem), 3 years after parathyroidectomy in 11
patients. In their study, published in 1998, all kidney
transplant recipients (transplanted between 1977 and 1992)
were on a corticoid based immunosuppression (predniso-
lone, cyclosporine, and/or azathioprine), ate a normal diet
(probably no calcium supplementation), and none of them
received vitamin D supplementation.
Milas and Weber showed a mean increase of
7.1 ± 6.4% in bone mass density of the hip, lumbar spine,
and forearm 23 ± 25 months after parathyroidectomy in a
subgroup of 16 patients with available pre- and postoper-
ative data, among 36 patients with tertiary
hyperparathyroidism. The date of kidney transplantation is
not mentioned is this subgroup of patients but, according to
the follow-up time, patients most likely received trans-
plants after 1995 [23].
Patients
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The present study shows an increase in BMD by
9.5 ± 8.0% at the spine and 9.5 ± 7.9% at the hip after a
median follow-up of 26 months after parathyroidectomy.
The BMD increased less in the study by Abdelhadi and
Nordenstrom, and there are different possible reasons
for that. First, their study is older than the two other.
Therefore, most of their patients probably did not receive a
bone-sparing immunosuppression regimen, as currently
recommended [1, 24]. The detrimental effects of long-term
immunosuppression, and particularly of corticoid therapy,
on bone mass is well established [8, 25–27], and, because
of prolonged survival after kidney transplantation, more
interest is now given to bone metabolism. In our study, one
patient was transplanted in 1986, the 13 others between
1996 and 2004. All of them had the lowest possible dose of
steroids, as demonstrated by the fact that 64% of them had
a steroid-free regimen at follow-up, compared to none of
their patients. Moreover, among different possible inter-
ventions to prevent bone loss after transplantation, vitamin
D supplementation has consistently demonstrated its effi-
cacy [27] and is currently recommended after renal
transplantation [1, 24, 27]. No patient in the study by
Abdelhadi and Nordenstrom received calcium and vitamin
D supplementation, whereas all patients in our study
received both. Second, the three studies were small (14
patients in ours, 16 in the study by Milas et al., and 13 at
2 years and 11 at 3 years in the study by Abdelhadi and
Nordenstrom), and the differences might not be statistically
significant. Third, the preoperative bone mass density is not
mentioned for the hip and spine in the subset of patients
with 3 HPT in the study by Abdelhadi and Nordenstrom,
and it may be that patients in the study by Milas et al. and
in our study had more advanced bone loss than their
patients. In effect, BMD increases more in patients and at
sites with lowest preoperative T-score, as also reported in
previous studies in primary and renal hyperparathyroidism
[22, 28].
Previous studies reported some BMD increase after the
immediate post-transplant period in some patients [4, 29];
however, the increase was never more than a few percent.
The[9% increase shown in the present study suggests that
it does not only occur as a result of spontaneous bone
change after better medical management. As all our
patients were followed by the same team from the time of
dialysis, it is anticipated that the medical treatment was
already the best possible before parathyroidectomy.
After parathyroidectomy for primary hyperparathyroid-
ism, the reported increase in BMD ranges between 3.2%
and 12.2% in different studies according to follow-up times
and severity of bone loss preoperatively [28, 30–32]. Our
study showing an increase of 9%–10% in hip and spine
BMD suggests that, in 3 HPT after renal transplantation,
results at least as good as those obtained in primary
hyperparathyroidism can be expected. This contrasts with
the hypothesis of Abdelhadi and Nordenstrom [22], who
suggested that performing a parathyroidectomy on kidney
transplant recipients could be too late from a bone-pre-
serving perspective.
Calcimimetics have been recently developed and may
offer an interesting alternative to parathyroidectomy in
patients with 3 HPT after renal transplantation in the
future. However, they are not currently approved for the
treatment of 3 HPT in most countries, leaving parathy-
roidectomy as the single option. The obligatory cessation
of calcimimetics after renal transplanation might lead to
rebound hyperparathyroidism and, while a decrease in the
prevalence of parathyroidectomy is currently seen in 2
HPT patients, an increase in the need for parathyroidec-
tomy in 3 HPT patients is anticipated by some authors [6].
Three recent series reported the use of Cinacalcet in kidney
transplant recipients [33–35]. All of them demonstrated its
efficacy in normalizing serum calcium level and its safety
on graft function. However, one study did not show any
change in PTH level [33], and the other two showed only
minimal decrease of PTH level (171 versus 148 pg/ml [35]
and 176 versus 135 pg/ml [34], before and after treatment,
respectively). Bone mineral density and bone markers were
not studied in these short-term studies (maximum
6 months). In primary hyperparathyroidism, calcimimetics
were similarly effective in normalizing serum calcium
levels; only slightly decreased PTH levels, however, did
not change BMD after 1 year [36], nor after 5 years. The
effects of calcimimetics on BMD in patients with 3 HPT
after transplantation are still awaited.
This study has several limitations; first, it is retrospec-
tive and therefore BMD analysis and blood and urine
sampling occurred at different time points after parathy-
roidectomy. However, the consistent increase in BMD
postoperatively suggests that this increase persists over
time, as previously demonstrated for primary hyperpara-
thyroidism [32]. Apart from small sample size, the
nonstandardized timing of blood and urine sampling might
be the reason for the nonsignificant difference in bone
markers pre- versus postoperatively. Second, the sample
size is small and heterogeneous in terms of patient char-
acteristics such as age, sex, kidney function, delay between
kidney transplantation and parathyroidectomy, not allow-
ing subset analysis of patients who would benefit more
from parathyroidectomy. Whether the BMD would
increase more after parathyroidectomy by waiting until the
patient reaches a baseline immunosuppression, if possible
steroid free, or whether the BMD would increase more if
parathyroidectomy were performed as early as possible
once the persistence of 3 HPT has been demonstrated, is an
important issue that needs further study.Third, the different
impact of the different procedures (parathyroidectomy,
World J Surg (2008) 32:1795–1801 1799
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steroid withdrawal, calcium and vitamin D supplementa-
tion) on BMD changes cannot be elucidated from this
study.
Conclusions
Subtotal parathyroidectomy is a safe and efficient treatment
to correct the calcium and PTH levels and to increase BMD
in patients with 3 HPT after renal transplantation. In the
present study, parathyroidectomy combined with bone-
preserving immunosuppression and calcium and vitamin D
supplementation led to a [10% increase of BMD in
patients with osteoporosis or osteopenia 2.2 years after
parathyroidectomy. Whether calcimimetics will have a
different impact on bone mineral density remains to be
investigated; however, so far, only parathyroidectomy has
been demonstrated to have such a beneficial effect on
BMD. Further studies are needed to show whether early
parathyroidectomy (3 months after renal transplantation
has been suggested by some authors [6]) could avoid
severe loss of BMD after renal transplantation. We there-
fore recommend parathyroidectomy in patients with 3 HPT
after renal transplantation and reduced bone mass density.
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